Akira Asai Selected Research

amarouciaxanthin A

2/2004

Biotransformation of fucoxanthinol into amarouciaxanthin A in mice and HepG2 cells: formation and cytotoxicity of fucoxanthin metabolites.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Akira Asai Research Topics

Disease

50	Neoplasms (Cancer) 07/2023 - 05/2003
9	Infections 11/2022 - 10/2010
9	Hepatocellular Carcinoma (Hepatoma) 06/2022 - 08/2007
7	Body Weight (Weight, Body) 01/2021 - 06/2012
7	Type 2 Diabetes Mellitus (MODY) 01/2020 - 09/2008
6	Neoplasm Metastasis (Metastasis) 01/2021 - 10/2019
5	Fibrosis (Cirrhosis) 10/2023 - 01/2020
5	Liver Diseases (Liver Disease) 11/2022 - 01/2013
5	Non-alcoholic Fatty Liver Disease 01/2021 - 01/2014
5	Atherosclerosis 12/2019 - 05/2009
5	Glioblastoma (Glioblastoma Multiforme) 10/2017 - 07/2013
5	Prostatic Neoplasms (Prostate Cancer) 06/2007 - 07/2003
4	Chronic Hepatitis B 02/2024 - 01/2021
4	Liver Cirrhosis (Hepatic Cirrhosis) 12/2023 - 03/2020
4	Insulin Resistance 01/2023 - 01/2015
4	Hyperglycemia 01/2023 - 08/2011
4	Lung Neoplasms (Lung Cancer) 02/2022 - 02/2004
4	Ascites 01/2022 - 01/2020
4	Colonic Neoplasms (Colon Cancer) 01/2016 - 04/2007
3	Carcinogenesis 01/2024 - 11/2016
3	Sarcopenia 11/2022 - 08/2021
3	Sepsis (Septicemia) 01/2021 - 07/2012
3	Glioma (Gliomas) 10/2017 - 03/2016
2	Hepatitis 04/2022 - 09/2021
2	Opportunistic Infections (Opportunistic Infection) 01/2022 - 02/2015
2	Fatty Liver 12/2021 - 09/2021
2	Mitochondrial Diseases (Mitochondrial Disease) 10/2021 - 06/2007
2	Dysbiosis 09/2021 - 01/2021
2	Hemorrhage 06/2021 - 02/2021
2	Obesity 05/2021 - 01/2020
2	Diabetes Mellitus 05/2021 - 01/2020
2	Liver Failure 02/2021 - 01/2020
2	Islet Cell Adenoma (Islet Cell Tumors) 01/2021 - 07/2017
2	Hypoglycemia (Reactive Hypoglycemia) 01/2021 - 07/2017
2	Surgical Wound Infection 01/2020 - 01/2018
2	Colorectal Neoplasms (Colorectal Cancer) 01/2016 - 04/2007
2	Glucose Intolerance 01/2014 - 06/2012
2	Lymphoma (Lymphomas) 05/2011 - 11/2010

Drug/Important Bio-Agent (IBA)

9	Glucose (Dextrose)FDA LinkGeneric 12/2021 - 08/2011
8	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 07/2023 - 03/2009
8	STX-0119IBA 10/2020 - 11/2010
7	Proteins (Proteins, Gene)FDA Link 12/2021 - 12/2009
5	DNA (Deoxyribonucleic Acid)IBA 03/2023 - 11/2010
5	Insulin (Novolin)FDA Link 01/2023 - 01/2015
5	CytokinesIBA 10/2021 - 11/2016
4	Immune Checkpoint InhibitorsIBA 07/2023 - 01/2019
4	YHO-1701IBA 07/2023 - 05/2020
4	SurvivinIBA 05/2020 - 03/2010
4	Blood Glucose (Blood Sugar)IBA 12/2019 - 06/2012
4	OligodeoxyribonucleotidesIBA 01/2018 - 07/2012
4	fucoxanthinIBA 08/2008 - 02/2004
4	neoxanthinIBA 08/2008 - 09/2004
3	tenofovir alafenamideIBA 02/2024 - 01/2021
3	AlbuminsIBA 10/2023 - 11/2013
3	Antiviral Agents (Antivirals)IBA 10/2023 - 04/2017
3	KynurenineIBA 01/2022 - 03/2012
3	Cisplatin (Platino)FDA LinkGeneric 11/2017 - 01/2017
3	Temozolomide (Temodar)FDA LinkGeneric 10/2017 - 07/2014
3	Interleukin-12 (IL 12)IBA 02/2015 - 10/2010
3	Interleukin-10 (Interleukin 10)IBA 07/2012 - 10/2010
3	Telomerase (Telomerase Reverse Transcriptase)IBA 02/2006 - 05/2003
3	Carotenoids (Carotene)IBA 03/2005 - 02/2004
2	Surface Antigens (Surface Antigen)IBA 01/2024 - 03/2023
2	NucleosidesIBA 01/2024 - 03/2023
2	alectinibIBA 02/2022 - 01/2021
2	Tyrosine Kinase InhibitorsIBA 02/2022 - 12/2019
2	TOR Serine-Threonine KinasesIBA 01/2022 - 03/2016
2	LipidsIBA 01/2022 - 01/2015
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 01/2019
2	AntigensIBA 01/2022 - 01/2019
2	Tryptophan (L-Tryptophan)FDA Link 01/2022 - 03/2012
2	Anti-Bacterial Agents (Antibiotics)IBA 09/2021 - 01/2021
2	A-factor (Streptomyces)IBA 05/2021 - 02/2004
2	3-tritylthio-L-alanineIBA 04/2021 - 12/2010
2	ProdrugsIBA 04/2021 - 01/2021
2	Insulin-Like Growth Factor II (Somatomedin A)IBA 01/2021 - 07/2017
2	Transcription Factors (Transcription Factor)IBA 10/2020 - 01/2019
2	LigandsIBA 08/2020 - 01/2020
2	AntibodiesIBA 01/2020 - 12/2019
2	phosphatidylcholine hydroperoxideIBA 02/2015 - 05/2009
2	Phosphatidylcholines (Phosphatidylcholine)IBA 02/2015 - 05/2009
2	Biomarkers (Surrogate Marker)IBA 07/2014 - 09/2011
2	GTP Phosphohydrolases (GTPases)IBA 01/2014 - 12/2009
2	N'- (3,4- dihydroxybenzylidene)- 3- hydroxy- 2- naphthahydrazideIBA 01/2014 - 12/2009
2	Dynamins (Dynamin)IBA 01/2014 - 12/2009
2	Phospholipids (Phosphatides)FDA LinkGeneric 03/2011 - 10/2008
2	TocotrienolsIBA 06/2010 - 02/2009
2	peridininIBA 03/2009 - 04/2007

Therapy/Procedure

19	Therapeutics 01/2024 - 03/2009
8	Hepatectomy 06/2022 - 10/2019
4	Drug Therapy (Chemotherapy) 10/2019 - 02/2006
3	Immunotherapy 07/2023 - 01/2019
3	Aftercare (After-Treatment) 02/2022 - 01/2018
3	Oral Administration 01/2022 - 11/2010
3	Glycemic Control 07/2018 - 11/2013
2	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022 - 12/2021
2	Length of Stay 09/2021 - 01/2018
2	Fecal Microbiota Transplantation 09/2021 - 01/2021
2	Radiofrequency Ablation 06/2021 - 08/2007
2	Radiotherapy 01/2021 - 01/2017